Answers are grounded in this paper and cite their sources.
// Julie Jacobs 1,2 , Karen Zwaenepoel 2 , Christian Rolfo 1,3,4 , Jolien Van den Bossche 1 , Christophe Deben 1 , Karen Silence 5 , Christophe Hermans 1,2 , Evelien Smits 1,6 , Paul Van Schil 7 , Filip Lardon 1 , Vanessa Deschoolmeester 1,2,* and Patrick Pauwels 1,2,* 1 Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium 2 Department of Pathology, Antwerp University Hospital, Edegem, Belgium 3 Department of Oncology, Antwerp University Hospital, Edegem, Belgium 4 Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium 5 arGEN-X BVBA, Ghent, Belgium 6 Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, Antwerp University, Wilrijk, Belgium 7 Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium * These authors are co-senior authors Correspondence to: Christian Rolfo, email: // Keywords : CD70, NSCLC, immunotherapy, targeted therapies Received : February 03, 2015 Accepted : April 03, 2015 Published : April 19, 2015 Abstract Although normally restricted to activated T and B cells and mature dendritic cells, constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid tumors, where it increases tumor cell and regulatory T cell survival by signaling through its receptor, CD27. We have assessed the co-expression of CD70 and CD27 in non-small cell lung cancer (NSCLC) by immunohistochemistry to explore a correlation between expression of the protein and tumor histologic subtype, genetic aberrations and prognosis. Furthermore, we tested the ability of ARGX-110, a CD70-blocking antibody, to induce NK cell-mediated cytotoxicity. Our results revealed CD70 expression on the surface of both primary and metastatic NSCLC tumor cells and in the tumor microenvironment. Moreover, CD27-expressing tumor infiltrating lymphocytes were found adjacent to the tumor cells, suggesting active CD70-mediated signaling. Finally, we have shown that ARGX-110, has potent cytotoxic effects on CD70 + NSCLC cell lines.
No takes yet. Share an insight, caveat, or question.
Jacobs et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: